Prognostic value of metastatic N1 lymph node ratio and angiolymphatic invasion in patients with pathologic stage IIA non-small cell lung cancer

Ching-Feng Wu, Ching-Yang Wu, Jui-Ying Fu, Chi-Wei Wang, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu, Ching-Feng Wu, Ching-Yang Wu, Jui-Ying Fu, Chi-Wei Wang, Yun-Hen Liu, Ming-Ju Hsieh, Yi-Cheng Wu

Abstract

With regard to pathologic stage IIA (pIIA) non-small cell lung cancer (NSCLC), there is a paucity of literature evaluating the risk factors for disease-free survival (DFS) and overall survival (OS). The aim of this study was to identify the prognostic factors of DFS and OS in patients with NSCLC pIIA.We performed a retrospective review of 98 stage II patients (7th edition of the American Joint Committee on Cancer) who underwent lung resection from January 2005 to February 2011. Of these, 23 patients were excluded for this study because of loss of follow-up or different substage, and 75 patients with pIIA were included for further univariate and multivariate analysis. Risk factors for DFS and OS were analyzed, including age, gender, smoking history, operation method, histology, differential grade, visceral pleural invasion, angiolymphatic invasion, and metastatic N1 lymph node ratio (LNR).Of the 75 patients with pIIA NSCLC who were examined, 29 were female and 46 were male, with a mean age of 61.8 years (range: 34-83 years). The average tumor size was 3.188 cm (range: 1.10-6.0 cm). Under univariate analysis, angiolymphatic invasion and metastatic N1 LNR were risk factors for DFS (P = 0.011, P = 0.007). Under multivariate analysis, angiolymphatic invasion and metastatic N1 LNR were all independent risk factors for DFS, while adjuvant chemotherapy and higher metastatic N1 LNR were independent prognostic factors for OS.For patients with pIIA, higher metastatic N1 LNR and angiolymphatic invasion were related to poor DFS. In addition to DFS, higher metastatic N1 LNR was also a poor prognostic factor for OS rates and adjuvant therapy effectiveness. Clinical physicians should devise different postsurgical follow-up programs depending on these factors, especially for patients with high risk.

Conflict of interest statement

The authors have no funding and conflicts of interest to disclose.

Figures

FIGURE 1
FIGURE 1
Overall survival of pathologic stage IIA patients with metastatic lymph node ratio, P = 0.011.
FIGURE 2
FIGURE 2
Disease-free survival of pathologic stage IIA patients with metastatic lymph node ratio, P = 0.008.
FIGURE 3
FIGURE 3
Disease-free survival of pathologic stage IIA patients with/without angiolymphatic invasion, P = 0.011.

References

    1. AJCC. American Joint Committee on Cancer (AJCC) cancer staging handbook. In: Edge SB, Byrd DR, Compton CC, et al. eds. Cancer Staging Manual. 7th ed Chicago, IL: Springer; 2010. 299–323.
    1. NCCN. National Comprehensive Cancer Network Guideline Version 2. 2013. .
    1. Wang J, Wu N, Zheng Q, Feng Y. Evaluation of the 7th edition of the TNM classification for lung cancer at a single institution. J Cancer Res Clin Oncol. 2014;140:1189–1195.
    1. Osaki T, Nagashima A, Yoshimatsu T, et al. Survival and characteristics of lymph node involvement in patients with N1 non-small cell lung cancer. Lung Cancer. 2004;43:151–157.
    1. Marra A, Hillejan L, Zaboura G, et al. Pathologic N1 non-small cell lung cancer: correlation between pattern of lymphatic spread and prognosis. J Thorac Cardiovasc Surg. 2003;125:543–553.
    1. Demir A, Turna A, Kocaturk C, et al. Prognostic significance of surgical-pathologic N1 lymph node involvement in non-small cell lung cancer. Ann Thorac Surg. 2009;87:1014–1022.
    1. Arriagada R, Bergman B, Dunant A, et al. ; International Adjuvant Lung Cancer Trial Collaborative Group. Cisplatin-based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer. N Engl J Med. 2004;350:351–360.
    1. Winton T, Livingston R, Johnson D, et al. ; National Cancer Institute of Canada Clinical Trials Group; National Cancer Institute of the United States Intergroup JBR. 10 Trial Investigators. Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer. N Engl J Med. 2005;352:2589–2597.
    1. Arriagada R, Dunant A, Pignon JP, et al. Long-term results of the international adjuvant lung cancer trial evaluating adjuvant cisplatin-based chemotherapy in resected lung cancer. J Clin Oncol. 2010;28:35–42.
    1. Pignon JP, Tribodet H, Scagliotti GV, et al. ; LACE Collaborative Group. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008;26:3552–3596.
    1. Taylor MD, Lapar DJ, Thomas CJ, et al. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell. Ann Thorac Surg. 2013;96:1163–1170.
    1. Li ZM, Ding ZP, Luo QQ, et al. Lung cancer prognostic significance of the extent of lymph node involvement in Stage II-N1 non-small cell lung cancer. Chest. 2013;144:1253–1260.
    1. Riquet M, Legras A, Mordant P, et al. Number of mediastinal lymph nodes in non-small cell lung cancer: a Gaussian curve, not a prognostic factor. Ann Thorac Surg. 2014. [Epub ahead of print].
    1. Kato H, Ichinose Y, Ohta M, et al. ; Japan Lung Cancer Research Group on Postsurgical Adjuvant Chemotherapy. A randomized trial of adjuvant chemotherapy with uracil–tegafur for adenocarcinoma of the lung. N Engl J Med. 2004;350:1713–1721.
    1. Travis WD, Brambilla E, Rami-Porta R, et al. ; International Staging Committee. Visceral pleural invasion: pathologic criteria and use of elastic stains. Proposal for the 7th edition of the TNM classification for lung cancer. J Thorac Oncol. 2008;3:1384–1390.
    1. Shimizu K, Yoshida J, Nagai K, et al. Visceral pleural invasion is an invasive and aggressive indicator of non-small cell lung cancer. J Thorac Cardiovasc Surg. 2005;130:160–165.
    1. Kato T, Ishikawa K, Aragaki M, et al. Angiolymphatic invasion exerts a strong impact on surgical outcomes for stage I lung adenocarcinoma, but not non-adenocarcinoma. Lung Cancer. 2012;77:394–400.
    1. Arame A, Mordant P, Cazes A, et al. Characteristics and prognostic value of lymphatic and blood vascular microinvasion in lung cancer. Ann Thorac Surg. 2012;94:1673–1679.
    1. Schuchert MJ, Schumacher L, Kilic A, et al. Impact of angiolymphatic and pleural invasion on surgical outcomes for stage I non-small cell lung cancer. Ann Thorac Surg. 2011;91:1059–1065.
    1. Groome PA, Bolejack V, Crowley JJ, et al. ; IASLC International Staging Committee; Cancer Research and Biostatistics; Observers to the Committee; Participating Institutions. The IASLC Lung Cancer Staging Project: Proposals for the Revision of the N Descriptors in the Forthcoming Seventh Edition of the TNM Classification for Lung Cancer. J Thorac Oncol. 2007;2:706–714.
    1. Schneider DF, Chen H, Sippel RS. Impact of lymph node ratio on survival in papillary thyroid cancer. Ann Surg Oncol. 2013;20:1906–1911.
    1. Allaix ME, Arezzo A, Cassoni P, et al. Metastatic lymph node ratio as a prognostic factor after laparoscopic total mesorectal excision for extraperitoneal rectal cancer. Surg Endosc. 2013;27:1957–1967.
    1. Chen S, Zhao BW, Li YF, et al. The prognostic value of harvested lymph nodes and the metastatic lymph node ratio for gastric cancer patients: results of a study of 1,101 patients. PLoS One. 2012;7:e49424.
    1. Shamseddine AI, Mukherji D, Melki C, et al. Lymph node ratio is an independent prognostic factor after resection of periampullary malignancies: data from a tertiary referral center in the Middle East. Am J Clin Oncol. 2014;37:13–18.
    1. Gohari MR, Khodabakhshi R, Shahidi J, et al. The impact of multiple recurrences in disease-free survival of breast cancer: an extended Cox model. Tumori. 2012;98:428–433.
    1. Polterauer S, Grimm C, Hofstetter G, et al. Nomogram prediction for overall survival of patients diagnosed with cervical cancer. Br J Cancer. 2012;107:918–924.
    1. Bhamidipati CM, Stukenborg GJ, Thomas CJ, et al. Pathologic lymph node ratio is a predictor of survival in esophageal cancer. Ann Thorac Surg. 2012;94:1643–1651.
    1. Wisnivesky JP, Arciniega J, Mhango G, et al. Lymph node ratio as a prognostic factor in elderly patients with pathological N1 non-small cell lung cancer. Thorax. 2011;66:287–293.
    1. Vinh-Hung V, Verkooijen HM, Fioretta G, et al. Lymph node ratio as an alternative to pN staging in node-positive breast cancer. J Clin Oncol. 2009;27:1062–1068.
    1. Bréchot JM, Chevret S, Charpentier MC, et al. Blood vessel and lymphatic vessel invasion in resected nonsmall cell lung carcinoma. Correlation with TNM stage and disease free and overall survival. Cancer. 1996;78:2111–2118.
    1. Higgins KA, Chino JP, Ready N, et al. Lymphovascular invasion in non-small-cell lung cancer: implications for staging and adjuvant therapy. J Thorac Oncol. 2012;7:1141–1147.
    1. Imai K, Minamiya Y, Saito H, et al. Detection of pleural lymph flow using indocyanine green fluorescence imaging in non-small cell lung cancer surgery: a preliminary study. Surg Today. 2013;43:249–254.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다